MULTIPLE-MODES OF LIGAND RECOGNITION - CRYSTAL-STRUCTURES OF CYCLIN-DEPENDENT PROTEIN-KINASE-2 IN COMPLEX WITH ATP AND 2 INHIBITORS, OLOMOUCINE AND ISOPENTENYLADENINE

被引:265
|
作者
SCHULZEGAHMEN, U
BRANDSEN, J
JONES, HD
MORGAN, DO
MEIJER, L
VESELY, J
KIM, SH
机构
[1] UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA
[2] UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA
[3] UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA
[4] CNRS, BIOL STN, F-29682 ROSCOFF, FRANCE
[5] UNIV PALACKY, FAC MED, DEPT PATHOPHYSIOL, CR-77515 OLOMOUC, CZECH REPUBLIC
关键词
X-RAY CRYSTALLOGRAPHY; PROTEIN KINASE INHIBITORS; CDK INHIBITOR SPECIFICITY; CANCER; DRUG DESIGN;
D O I
10.1002/prot.340220408
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. Mitogenic or growth inhibitory signals are mediated, respectively, by activation or inhibition of CDKs which phosphorylate proteins associated with the cell cycle. The central role of CDKs in cell cycle regulation makes them a potential new target for inhibitory molecules with anti-proliferative and/or anti-neoplastic effects. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(Delta(2)-isopentenyl)adenine, and a strongly specific inhibitor, olomoucine. Both inhibitors are adenine derivatives and bind in the adenine binding pocket of CDK2, but in an unexpected and different orientation from the adenine of the authentic ligand ATP. The N6-benzyl substituent in olomoucine binds outside the conserved binding pocket and is most likely responsible for its specificity. The structural information from the CDK2-olomoucine complex will be useful in directing the search for the next generation inhibitors with improved properties. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:378 / 391
页数:14
相关论文
共 27 条
  • [1] High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: Bound waters and natural ligand as guides for inhibitor design
    SchulzeGahmen, U
    DeBondt, HL
    Kim, SH
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (23) : 4540 - 4546
  • [2] Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2
    Johnson, LN
    De Moliner, E
    Brown, NR
    Song, HW
    Barford, D
    Endicott, JA
    Noble, MEM
    PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) : 113 - 124
  • [3] Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds
    Havlicek, L
    Hanus, J
    Vesely, J
    Leclerc, S
    Meijer, L
    Shaw, G
    Strnad, M
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (04) : 408 - 412
  • [4] Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth
    Mendoza, N
    Fong, S
    Marsters, J
    Koeppen, H
    Schwall, R
    Wickramasinghe, D
    CANCER RESEARCH, 2003, 63 (05) : 1020 - 1024
  • [5] Ligand binding affinity determined by temperature-dependent circular dichroism: Cyclin-dependent kinase 2 inhibitors
    Mayhood, TW
    Windsor, WT
    ANALYTICAL BIOCHEMISTRY, 2005, 345 (02) : 187 - 197
  • [6] The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity
    Alessi, F
    Quarta, S
    Savio, M
    Riva, F
    Rossi, L
    Stivala, LA
    Scovassi, AI
    Meijer, L
    Prosperi, E
    EXPERIMENTAL CELL RESEARCH, 1998, 245 (01) : 8 - 18
  • [7] Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors
    Adams, PD
    Sellers, WR
    Sharma, SK
    Wu, AD
    Nalin, CM
    Kaelin, WG
    MOLECULAR AND CELLULAR BIOLOGY, 1996, 16 (12) : 6623 - 6633
  • [8] Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma
    Ely, S
    Di Liberto, M
    Niesvizky, R
    Baughn, LB
    Cho, HJ
    Hatada, EN
    Knowles, DM
    Lane, J
    Chen-Kiang, S
    CANCER RESEARCH, 2005, 65 (24) : 11345 - 11353
  • [9] Tobacco retinoblastoma-related protein phosphorylated by a distinct cyclin-dependent kinase complex with Cdc2/cyclin D in vitro
    Nakagami, H
    Sekine, M
    Murakami, H
    Shinmyo, A
    PLANT JOURNAL, 1999, 18 (03): : 243 - 252
  • [10] Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717
    Dreyer, MK
    Borcherding, DR
    Dumont, JA
    Peet, NP
    Tsay, JT
    Wright, PS
    Bitonti, AJ
    Shen, J
    Kim, SH
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) : 524 - 530